Abstract
Chimeric antigen receptor (CAR) T cell therapy for solid tumors shows promise, but several hurdles remain. Strategies to overcome barriers such as CAR T therapy-related toxicities (CTT), immunosuppression, and immune checkpoints through research and technology are needed to put the last nail to the coffin and offer hope for previously incurable malignancies. Herein we review current literature and infer novel strategies for the mitigation of CTT while impeding immune suppression, stromal barriers, tumor heterogeneity, on-target/off-tumor toxicities, and better transfection strategies with an emphasis on clinical research and prospects.
Keywords:
CAR T; immune checkpoints; immunosuppression; stromal barrier; transfection strategies.
Copyright © 2023 Khawar, Ge, Afzal and Sun.
Publication types
-
Review
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Humans
-
Neoplasms* / therapy
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Chimeric Antigen* / genetics
-
T-Lymphocytes
-
Thrombocytopenia*
-
Tumor Microenvironment
Substances
-
Receptors, Chimeric Antigen
-
Receptors, Antigen, T-Cell
Grants and funding
This study was funded in part by the Startup Foundation for Advanced Talents and Science and Technology Innovation Foundation at Yangzhou University (HS), the Innovative Training Grant of College Students in Jiangsu Province (202111117097Y, FG and HS), and Postgraduate Research and Practice Innovation Program of Jiangsu Province (SJCX21_1655). This study was funded in part by The Medical Research Project of Jiangsu Provincial Health Commission (M2022024); Scientific Research Project of Nantong Municipal Health Commission (MS2022102) and Natural Science Foundation of Nanjing University of Traditional Chinese Medicine (no.XZR2020084).